Brian Cheng
Stock Analyst at J.P. Morgan
(4.53)
# 999
Out of 4,468 analysts
253
Total ratings
56.3%
Success rate
13.6%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Maintained: Buy | n/a | $4.06 | - | 5 | Jun 30, 2026 | |
| IMNM Immunome | Maintained: Buy | n/a | $23.61 | - | 9 | Jun 29, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $200 | $189.24 | +5.69% | 14 | Jun 25, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | n/a | $113.51 | - | 6 | Jun 25, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | $26 | $16.74 | +55.32% | 1 | Jun 2, 2026 | |
| EIKN Eikon Therapeutics | Maintained: Buy | n/a | $12.54 | - | 4 | May 31, 2026 | |
| TGTX TG Therapeutics | Reiterated: Buy | n/a | $53.31 | - | 2 | May 27, 2026 | |
| IMVT Immunovant | Maintained: Buy | $35 → $47 | $38.79 | +21.17% | 11 | May 26, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $35 → $40 | $35.13 | +13.86% | 23 | May 26, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Sell | $8 | $17.56 | -54.44% | 17 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $106 → $113 | $131.62 | -14.15% | 22 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $8.89 | +226.21% | 8 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $89 | $83.31 | +6.83% | 9 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $13 → $14 | $15.00 | -6.67% | 15 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $31 | $24.21 | +28.05% | 2 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $96 | $70.36 | +36.44% | 9 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $88 | $83.99 | +4.77% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $2.08 | - | 8 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 → $46 | $18.19 | +152.89% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $34.79 | - | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $3.65 | - | 7 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $26.31 | - | 13 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $69 → $67 | $60.08 | +11.52% | 3 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.16 | - | 2 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.52 | - | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $11.62 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $5.64 | - | 6 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.19 | n/a | 8 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.19 | n/a | 7 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.45 | n/a | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $6 | $1.26 | n/a | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $20 → $6 | $9.00 | n/a | 3 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.07 | n/a | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $0.1732 | n/a | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 → $3.5 | $1.81 | n/a | 2 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $17 | $9.84 | n/a | 6 | Apr 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.07 | n/a | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $93 → $86 | $7.28 | n/a | 5 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $2.91 | n/a | 2 | Nov 2, 2021 |
Protara Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: n/a
Current: $4.06
Upside: -
Immunome
Jun 29, 2026
Maintained: Buy
Price Target: n/a
Current: $23.61
Upside: -
Revolution Medicines
Jun 25, 2026
Reiterated: Buy
Price Target: $200
Current: $189.24
Upside: +5.69%
Kymera Therapeutics
Jun 25, 2026
Maintained: Buy
Price Target: n/a
Current: $113.51
Upside: -
Odyssey Therapeutics
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $16.74
Upside: +55.32%
Eikon Therapeutics
May 31, 2026
Maintained: Buy
Price Target: n/a
Current: $12.54
Upside: -
TG Therapeutics
May 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $53.31
Upside: -
Immunovant
May 26, 2026
Maintained: Buy
Price Target: $35 → $47
Current: $38.79
Upside: +21.17%
Roivant Sciences
May 26, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $35.13
Upside: +13.86%
Intellia Therapeutics
May 13, 2026
Maintained: Sell
Price Target: $8
Current: $17.56
Upside: -54.44%
May 13, 2026
Maintained: Buy
Price Target: $106 → $113
Current: $131.62
Upside: -14.15%
May 13, 2026
Rated: Buy
Price Target: $29
Current: $8.89
Upside: +226.21%
May 11, 2026
Maintained: Buy
Price Target: $80 → $89
Current: $83.31
Upside: +6.83%
May 11, 2026
Rated: Hold
Price Target: $13 → $14
Current: $15.00
Upside: -6.67%
May 11, 2026
Rated: Buy
Price Target: $30 → $31
Current: $24.21
Upside: +28.05%
May 11, 2026
Rated: Buy
Price Target: $96
Current: $70.36
Upside: +36.44%
May 1, 2026
Initiated Coverage: Buy
Price Target: $88
Current: $83.99
Upside: +4.77%
Apr 16, 2026
Upgraded: Hold
Price Target: n/a
Current: $2.08
Upside: -
Apr 15, 2026
Maintained: Buy
Price Target: $47 → $46
Current: $18.19
Upside: +152.89%
Mar 25, 2026
Maintained: Buy
Price Target: n/a
Current: $34.79
Upside: -
Mar 13, 2026
Maintained: Sell
Price Target: n/a
Current: $3.65
Upside: -
Mar 3, 2026
Maintained: Buy
Price Target: n/a
Current: $26.31
Upside: -
Feb 13, 2026
Maintained: Buy
Price Target: $69 → $67
Current: $60.08
Upside: +11.52%
Dec 4, 2025
Reiterated: Sell
Price Target: n/a
Current: $1.16
Upside: -
Nov 20, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.52
Upside: -
Oct 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $11.62
Upside: -
Aug 15, 2025
Upgraded: Hold
Price Target: n/a
Current: $5.64
Upside: -
Mar 21, 2025
Rated: Hold
Price Target: n/a
Current: $1.19
Upside: n/a
Sep 13, 2024
Rated: Hold
Price Target: n/a
Current: $4.19
Upside: n/a
Jul 15, 2024
Maintained: Hold
Price Target: n/a
Current: $1.45
Upside: n/a
May 2, 2024
Downgraded: Hold
Price Target: $16 → $6
Current: $1.26
Upside: n/a
Jun 1, 2023
Downgraded: Hold
Price Target: $20 → $6
Current: $9.00
Upside: n/a
Dec 16, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $1.07
Upside: n/a
Dec 7, 2022
Downgraded: Sell
Price Target: n/a
Current: $0.1732
Upside: n/a
Apr 19, 2022
Maintained: Buy
Price Target: $33 → $3.5
Current: $1.81
Upside: n/a
Apr 8, 2022
Reiterated: Buy
Price Target: $21 → $17
Current: $9.84
Upside: n/a
Apr 4, 2022
Reiterated: Buy
Price Target: $12
Current: $1.07
Upside: n/a
Mar 1, 2022
Maintained: Buy
Price Target: $93 → $86
Current: $7.28
Upside: n/a
Nov 2, 2021
Maintained: Buy
Price Target: $14
Current: $2.91
Upside: n/a